ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
195.6 EUR
+2.2 (+1.14%)
4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 82 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 4AB was profitable.
4AB had a positive operating cash flow in the past year.
Each year in the past 5 years 4AB has been profitable.
In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 4AB (1.75%) is better than 71.95% of its industry peers.
4AB has a Return On Invested Capital of 15.64%. This is amongst the best in the industry. 4AB outperforms 90.24% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 12.14%.
The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
Looking at the Profit Margin, with a value of 3.94%, 4AB is in the better half of the industry, outperforming 75.61% of the companies in the same industry.
4AB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 33.05%, 4AB belongs to the best of the industry, outperforming 87.80% of the companies in the same industry.
In the last couple of years the Operating Margin of 4AB has declined.
The Gross Margin of 4AB (71.16%) is better than 60.98% of its industry peers.
In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
The number of shares outstanding for 4AB remains at a similar level compared to 1 year ago.
4AB has more shares outstanding than it did 5 years ago.
4AB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.48 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
4AB has a Altman-Z score of 2.48. This is in the better half of the industry: 4AB outperforms 68.29% of its industry peers.
The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.49, 4AB is in the better half of the industry, outperforming 76.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.48 |
ROIC/WACC1.88
WACC8.33%
2.3 Liquidity
A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
The Current ratio of 4AB (0.72) is worse than 79.27% of its industry peers.
A Quick Ratio of 0.60 indicates that 4AB may have some problems paying its short term obligations.
The Quick ratio of 4AB (0.60) is worse than 80.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
Measured over the past 5 years, 4AB shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
The Revenue has been growing slightly by 7.40% in the past year.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.69% yearly.
Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.42% on average per year.
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
4AB is valuated rather expensively with a Price/Earnings ratio of 24.39.
78.05% of the companies in the same industry are more expensive than 4AB, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.59. 4AB is around the same levels.
4AB is valuated correctly with a Price/Forward Earnings ratio of 15.87.
90.24% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
4AB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.39 | ||
| Fwd PE | 15.87 |
4.2 Price Multiples
74.39% of the companies in the same industry are more expensive than 4AB, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 84.15% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.7 | ||
| EV/EBITDA | 16.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
4AB has a very decent profitability rating, which may justify a higher PE ratio.
4AB's earnings are expected to grow with 16.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.35
PEG (5Y)9.71
EPS Next 2Y19.81%
EPS Next 3Y16.75%
5. Dividend
5.1 Amount
4AB has a Yearly Dividend Yield of 3.09%.
4AB's Dividend Yield is rather good when compared to the industry average which is at 0.80. 4AB pays more dividend than 96.34% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, 4AB pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
5.2 History
The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
489.69% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
FRA:4AB (12/23/2025, 7:00:00 PM)
195.6
+2.2 (+1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.96%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap345.70B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts77.89
Price Target213.25 (9.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
Yearly Dividend5.33
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)1.8%
PT rev (3m)12.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)0.91%
EPS NY rev (3m)-11.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.39 | ||
| Fwd PE | 15.87 | ||
| P/S | 6.83 | ||
| P/FCF | 20.7 | ||
| P/OCF | 19.53 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.69 |
EPS(TTM)8.02
EY4.1%
EPS(NY)12.33
Fwd EY6.3%
FCF(TTM)9.45
FCFY4.83%
OCF(TTM)10.01
OCFY5.12%
SpS28.63
BVpS-1.27
TBVpS-44.45
PEG (NY)3.35
PEG (5Y)9.71
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.48 |
F-Score7
WACC8.33%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.29%
EBIT Next 3Y15.46%
EBIT Next 5Y11.36%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?
The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 24.39 and the Price/Book (PB) ratio is -154.22.
Can you provide the expected EPS growth for 4AB stock?
The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 7.28% in the next year.